NGM Biopharmaceuticals. has filed a patent for a complex containing a GDF15 polypeptide. The patent claims methods of treating individuals with metabolism disorders, such as glucose metabolism disorder and body weight disorder, along with associated compositions. GlobalData’s report on NGM Biopharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights NGM Biopharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on NGM Biopharmaceuticals, Human telomerase RT biomarker was a key innovation area identified from patents. NGM Biopharmaceuticals's grant share as of September 2023 was 32%. Grant share is based on the ratio of number of grants to total number of patents.

Complex for treating metabolism and body weight disorders

Source: United States Patent and Trademark Office (USPTO). Credit: NGM Biopharmaceuticals Inc

A recently filed patent (Publication Number: US20230312696A1) describes an antibody that specifically binds to a GDF15 mutein, which is a modified version of the GDF15 protein. The GDF15 mutein has at least one N-linked glycosylation consensus site and is conjugated to a first polypeptide that includes an IgG Fc sequence. This first polypeptide dimerizes with a second polypeptide that also includes an IgG Fc sequence. The second polypeptide has a CH3 sequence with at least one engineered cavity. The complex formed by the first and second polypeptides, along with the GDF15 mutein, has been shown to reduce food intake and/or body weight in diet-induced obese mice.

The patent also includes claims related to the nucleic acids encoding the first and second polypeptides, as well as the GDF15 mutein. The first polypeptide includes a first human IgG1 Fc sequence with specific substitutions, while the second polypeptide includes a second human IgG1 Fc sequence with different substitutions. The GDF15 mutein is conjugated to either the C-terminus of the first polypeptide or the C-terminus of the second polypeptide via a linker. The linker consists of multiple copies of a specific amino acid sequence. The GDF15 mutein itself has a specific amino acid sequence and includes a DST substitution relative to a reference sequence.

The patent also covers the use of vectors and host cells for producing the complex formed by the first and second polypeptides with the GDF15 mutein. Methods for producing the complex involve culturing the host cells and isolating the complex.

Overall, this patent describes an antibody that binds to a modified version of the GDF15 protein and forms a complex with two polypeptides. The complex has shown potential for reducing food intake and body weight in obese mice. The patent also covers the nucleic acids, vectors, host cells, and methods involved in producing the complex.

To know more about GlobalData’s detailed insights on NGM Biopharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies